Type 2 Diabetes Market by Leading Players Eli Lilly and Co., Sanofi Aventis A/S, Novo Nordisk, Merck & Co., Inc., Chugai Pharmaceutical Co., Bristol-Myers Squibb, Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., and AstraZeneca Plc.

Type 2 diabetes (T2D) is a chronic disease that affects bodys blood sugar level. Elevated blood sugar level (hyperglycemia) causes detrimental effects on heart, kidneys, eyes, blood vessels, and nerves.

The key players operating in the market include Eli Lilly and Co., Sanofi Aventis A/S, Novo Nordisk, Merck & Co., Inc., Chugai Pharmaceutical Co., Bristol-Myers Squibb, Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., and AstraZeneca Plc.

The major factor that drive the growth of the global type 2 diabetes (T2D) market are increase in prevalence of T2D disease globally. As per NCBI, 89 million cases of T2DM were recorded in 2014, and its prevalence is expected to reach to 330 million cases by 2022.

Get the sample PDF copy @ https://www.alliedmarketresearch.com/request-toc-and-sample/3964

Moreover, advancements in diabetic medications by pharmaceutical manufacturers fuel the market growth. Jardiance, a sodiumglucose cotransporter 2 inhibitor, and Tanzeum & Trulicity, two glucagon-like peptide-1 receptor agonists are the newest medications introduced in the market. However, lack of awareness among patients towards the availability of such medications restrains the market growth. Conversely, unmet medical needs in emerging economies are expected to provide lucrative growth opportunities for the market.

The report segments the global type 2 diabetes market based on drug class, application, and geography. On the basis of drug class, the market is categorized into dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, thiazolidinediones, alpha-glucosidase inhibitors, sulfonylureas & other insulin secretagogues, biguanides, and sodiumglucose cotransporter 2 inhibitors. In terms of application, it is divided into glycemic control, cardiovascular safety, hypoglycemia avoidance, and others. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Type 2 Diabetes Market Key Segments:

By Drug Class

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Thiazolidinediones
Alpha-glucosidase Inhibitors
Sulfonylureas & Other Insulin Secretagogues
Biguanides
SodiumGlucose Cotransporter 2 Inhibitors

Do purchase inquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/3964

By Application

Glycemic Control
Cardiovascular Safety
Hypoglycemia Avoidance
Others

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.